secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001104659-24-009551
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA reminds providers PEDMARK is not substitutable with other STS products
--------------------------------------------------------------------------

- FDA publicly warned healthcare providers that PEDMARK (sodium thiosulfate injection) must not be substituted with other STS products.
- Substitution risks include potassium chloride exposure (cardiac events) and overexposure to boric acid or sodium nitrite.
- PEDMARK is the only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric solid tumor patients.
- Fennec holds orphan drug exclusivity in the U.S. through 2029 for PEDMARK.
- FDA reminder reinforces PEDMARK's prescribing label and protects product from off-label compounding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924009551/0001104659-24-009551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924009551/tm244893d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-009551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer